UK to tackle low cancer survival rates
This article was originally published in Clinica
The UK National Health Service is to inject an additional £80 million ($128.5 million) into various provisions aimed at cutting cancer death rates by 20% in the next 10 years. The move follows the NHS' recent shift in priorities to concentrate on prevention and treatment of heart disease and cancer (see Clinica No 881, p 2).
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.